Catalogue Number: 10389-IBL
|Manufacturer:||IBL - (Immuno-Biologicals Laboratories Co Ltd)|
|Physical state:||Lyophilized product from PBS containing 1 % BSA and 0.05 % NaN3|
|Type:||Monoclonal Primary Antibody - Unconjugated|
|Shipping Condition:||Blue Ice|
|Unit(s):||100 ug, 10 ug|
|Immunogen:||Synthetic peptide of a part of human IDH1 R132H|
Description: Specific mutations in the isocitrate dehydrogenase 1 gene IDH1 have been found in several brain tumors including astrocytoma, oligodendroglioma and glioblastoma multiforme, with mutations found in nearly all cases of secondary glioblastomas, but rarely in primary high-grade glioblastoma multiforme. Individuals whose tumor had an IDH1 mutation had longer survival. Another report shows that mutations of IDH2 and IDH1 were found in up to 20 % of cytogenetically normal acute myeloid leukemia (AML). These mutations are known to produce 2-hydroxyglutarate (2HG) from alpha-ketoglutarate, and it is suggested that high 2HG levels may trigger epigenetic changes within the cells and the development of cancer. The IDH1 mutations are remarkably specific to a single codon in the conserved and functionally important Arginine 132 residue (R132) in IDH1. This antibody is developed as a monoclonal antibody which can specifically detect R132H mutation of IDH.
React with human IDH1-R132H. Not react with human IDH1 wild-type or the other IDH1 mutations.